Adnexal Neoplasm — Variants & evidence

Adnexal Neoplasm — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

152 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 151–152 of 152 evidence items (2 on this page mapped to a descendant entity) · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
VPS37A Underexpression1
Cetuximab	Malignant Ovarian Neoplasm	Predictive	D	Supports Resistance	3	accepted	EID1981 Vps37A-deficient ovarian cancer cells become irresponsive to inhibition by the therapeutic antibody cetuximab in-vitro. PMID 22016507 · Wittinger et al., 2011 · Open in CIViC	civic
ZNF217 Overexpression1
(prognostic)	Malignant Ovarian Neoplasm	Prognostic	B	Supports Poor Outcome	3	submitted	EID12207 ZNF217 was overexpressed in 60% of ovarian tumour samples (26/44) as demonstrated by immunohistochemistry (IHC). Patients with ZNF217 expression had significantly shorter disease-free survival compare… (full text at CIViC) PMID 25031722 · Li et al., 2014 · Open in CIViC	civic

Data updated 17 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.